-+ 0.00%
-+ 0.00%
-+ 0.00%
Otsuka Pharmaceutical's world's first IgA nephrodisease-targeting biologic agent, sibelizumab injection, was included in the 2026 National Medical Insurance Drug List to reduce proteinuria in adult patients with primary immunoglobulin A nephropathy at risk of disease progression.
Share
Listen to the news
Otsuka Pharmaceutical's world's first IgA nephrodisease-targeting biologic agent, sibelizumab injection, was included in the 2026 National Medical Insurance Drug List to reduce proteinuria in adult patients with primary immunoglobulin A nephropathy at risk of disease progression.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending